- Company
- Roche’s Lunsumio and Columvi win approval in Korea
- by Jan 5, 2024 05:41am
- Roche's Lunsumio and Columvi are the first bispecific antibodies for lymphoma treatment, showing effectiveness as a third-line treatment for patients with lymphoma. These two drugs are highly regarded for their clinical advantages, as they have additional specific antigen-binding sites compared to monoclonal antibodies. Roche Korea hel
- Company
- Pharma CEOs consider job cuts and reducing hiring in 2024
- by Kim, Jin-Gu Jan 5, 2024 05:41am
- 13% of pharmaceutical and bio company CEOs have announced plans to reduce employment this year. Apart from this, another 12% have indicated the possibility of reducing their workforce this year. Overall, the industry held a more cautious stance toward hiring this year. Compared to last year, the number of respondents who responded that
- Company
- Koselugo commences prescription with insurance coverage
- by Eo, Yun-Ho Jan 5, 2024 05:41am
- Hospitals have started prescribing Koselugo, a treatment for pediatric neurofibromatosis. AstraZeneca Korea’s Koselugo (ingredient: selumetinib), a neurofibromatosis, has recently passed the Drug Committee (DC) of tertiary hospitals, including Seoul National University Hospital, Samsung Seoul Hospital, Seoul St. Mary's Hospital, Seoul
- Policy
- Need to specify conditions for postponing PE data submission
- by Lee, Tak-Sun Jan 5, 2024 05:41am
- The results of the research service that was ordered by the Health Insurance Review and Assessment Service to devise measures on improving the pharmacoeconomic data submission waiver system, or the PE exemption system, have been disclosed in full. The improvements suggested by the researchers include redesigning the PE exemption system i
- Company
- Celltrion to divest prescription drugs acquired from Takeda
- by Kim, Jin-Gu Jan 4, 2024 05:33am
- The Celltrion group is selling divestiture of primary care business rights in the Asia-Pacific region acquired from Takeda Pharmaceutical in 2020. Among the business rights acquired from the previous deal, Celltrion group will initiate the sales of business rights for prescription drugs, excluding those intended for the domestic market
- Company
- Industry is less inclined to expand investment this year
- by Kim, Jin-Gu Jan 4, 2024 05:33am
- One in four CEOs of pharma and biotech companies announced that they will expand their investment in 2024. This is down by half compared to the response received in the survey last year when one in two CEOs said they would expand investment. This is likely a reflection of the growing economic uncertainty in Korea and abroad. 1 in
- Policy
- Moderna produced the most drugs in Korea in 2023
- by Lee, Hye-Kyung Jan 4, 2024 05:33am
- Moderna Korea has surpassed Celltrion and Hanmi Pharmaceutical and became the largest domestic pharmaceutical manufacturer in Korea in 2022. The item that drove Moderna’s lead was the COVID-19 vaccine ‘Spikevax Inj,’, which accounted for 100% of Moderna Korea's total production value of KRW 1.275 trillion. According to the '2023 Food an
- Company
- New CKD drug Kerendia is expected to receive reimb soon
- by Eo, Yun-Ho Jan 4, 2024 05:33am
- New chronic kidney disease drug ‘Kerendia’ is expected to receive reimbursement status. According to the industry, Bayer has reached a settlement with National Health Insurance Service (NHIS) in negotiations for the reimbursement pricing of its drug Kerendia(finerenone), which is used to treat chronic kidney disease in patients with t
- Company
- Only 1 of 10 CEOs ‘positive’ about drug regulations in KOR
- by Chon, Seung-Hyun Jan 3, 2024 07:28pm
- A survey showed only 1 in 10 CEOs of pharmaceutical companies were found to be satisfied with the Korean health authorities' regulatory policies for the pharmaceutical industry. In all major regulatory areas such as approvals, drug pricing, and sales, the satisfaction rate of CEOs was more negative than positive towards the set regulations.
- Product
- KPDS demands gov. action to end chemotherapy drug shortages
- by Kang, Hye-Kyung Jan 3, 2024 05:40am
- The Korean Pharmacists for Democratic Society (CEO: Hyeong-geun Shin, KPDS) has criticized the government’s system for the stable supply of essential medicines. The KPDS stated on the 28th that “5-fluorouracil, referred to as 5-FU, is a chemotherapy drug used to treat several types of cancers, including colorectal cancer, esophageal c
